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Abstract
Background: The relationship between fecal calprotectin (FC) and disease extent in ulcerative colitis (UC) has not
been fully elucidated. The aim of this study was to clarify the correlation of FC with disease extent and severity in
UC patients.
Methods: UC patients scheduled to undergo an ileocolonoscopy were enrolled and fecal samples for FC
measurement were collected prior to the procedure. A Mayo endoscopic subscore (MES) was determined for each
of 5 colonic segments. To evaluate the association of FC with extent of affected mucosa as well as disease severity,
we assessed the correlation of FC level with the sum of MES (S-MES) for the 5 colonic segments as compared to
the maximum score of MES (M-MES).
Results: FC measurements in conjunction with findings from 136 complete colonoscopies in 102 UC patients were
evaluated. FC level showed a stronger correlation with S-MES (correlation coefficient r = 0.86, p < 0.001) as compared to
M-MES (r = 0.79, p < 0.001). In patients with an M-MES of 1, 2, and 3, FC level showed a significant correlation with
S-MES (r = 0.67, p < 0.001; r = 0.70, p < 0.001; r = 0.47, p = 0.04, respectively). Our findings indicate that FC level
is elevated in patients with greater areas of affected mucosa even in those with the same M-MES value.
Conclusions: FC level was shown to be correlated with the extent of affected mucosa as well as severity in UC
patients, thus it is useful for precise assessment of mucosal inflammation.
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Background
Ulcerative colitis (UC) is a chronic idiopathic disorder
characterized by mucosal inflammation in the colon
and rectum. In recent years, management of UC has
substantially changed, with newly introduced treatments
such as biologics and tacrolimus shown to result in signifi-
cant endoscopic improvement as well as clinical remission
in some cases [1–8]. Therefore, endoscopic mucosal
healing (MH), which is associated with sustained clinical
remission and reduced rates of hospitalization and
surgical resection, has emerged as a major treatment
goal for UC patients [9–11]. Although an endoscopy
is recognized as the most reliable method for evaluating
MH, that examination is relatively invasive and sometimes
painful, while a colonoscopy procedure may exacerbate
UC [12]. As a result, it is difficult to perform frequent
endoscopic assessments of affected mucosa in clinical
practice and alternative noninvasive methods are neces-
sary for assessment of mucosal inflammation associated
with UC.
Calprotectin is a 36-kDa calcium- and zinc-binding
protein that represents most of the cytosolic proteins of
granulocytes [13]. Measurement of fecal calprotectin
(FC), which is stable for up to 3 days at room
temperature and resistant to degradation [14], is useful,
as its level reflects migration of neutrophils through the
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inflamed bowel wall to the mucosa and has been widely
utilized to clarify its correlation with endoscopically
proven UC activity [15–21]. Based on previously re-
ported data showing a strong correlation with endo-
scopic activity, noninvasive measurement of FC level has
been proposed to provide a reliable surrogate marker of
mucosal inflammation associated with UC [22].
Numerous scoring systems have been developed for
assessment of endoscopic activity in UC patients, of
which the Mayo endoscopic subscore (MES) is one of
the most widely employed endoscopic indices [23]. MES
is divided into 4 points (0–3) based on proctosigmoiddo-
scopic appearance. When an ileocolonoscopy is per-
formed, MES is often regarded as the maximum score
for the parts of the colorectum examined. In addition,
most other endoscopic indices also use such a maximum
score for assessment of colonic mucosal activity [24–27].
In previous reports of the correlation of FC with muco-
sal activity, the endoscopic scores used were those ob-
tained for the most severe level of inflammation in the
colorectum and disease extent was not considered to be
related to UC for evaluating the clinical usefulness of
FC. In this regard, the correlation of FC with disease ex-
tent in UC has not been fully investigated.
In the present study, we assessed the sum of MES
(S-MES) for the 5 colonic segments in patients with UC
who underwent a complete colonoscopy. To clarify the
correlation of FC with extent of affected mucosa as well as
disease severity, we investigated the correlation of FC level
with S-MES as compared to the maximum score of MES
(M-MES).
Methods
This study was prospectively conducted from February
2013 to December 2014 at Shimane University Hospital
and Matsue Seikyo General Hospital in Japan. The
protocol was approved by the ethical committees of both
hospitals and all patients gave written informed consent,
and the study was performed in adherence to the
Helsinki Declaration.
Patients
Patients with a previously established diagnosis of UC and
scheduled to undergo an ileocolonoscopy were enrolled.
For those who were outpatients, we asked them to obtain
fecal samples within 7 days before the ileocolonoscopy,
which were brought to the hospital or sent by postal mail
immediately after collection. Fecal samples from inpa-
tients were obtained the day before the ileocolonoscopy
and examined in the hospital laboratory. Patients who
previously underwent a sigmoidoscopy, or with a history
of colorectal surgery, acute infectious enterocolitis, or
regular intake of aspirin and/or other nonsteroidal anti-
inflammatory drugs (NSAIDs) were excluded from this
study. Those unable to provide a fecal sample were also
excluded. When exacerbation of symptoms such as diar-
rhea and melena were noted prior to the ileocolonoscopy
examination, we performed a stool culture for diagnosis of
pathogenic bacteria infection including Clostridium difficile,
as well as serum and histological examinations to exclude
CMV infection, as necessary. For patient demographics,
age, sex, duration of disease, clinical activity, extent
type of UC, and concomitant medications being taken
at each colonoscopic examination were noted. The
extent type of UC was determined according to the
Montreal classification based on previous colonoscopic
findings, unless the extent of affected mucosa based on
the present colonoscopic findings revealed more extensive
involvement [28, 29].
Fecal calprotectin measurement
Collected fecal samples used for FC measurements were
stored at −20 °C until shipment to the laboratory (SRL
Inc., Tokyo, Japan), where the FC level was determined
with the examiner blinded to the endoscopic findings
using a quantitative enzyme-linked immunosorbent assay
(PhiCal®, Immundiagnostik, Germany), with a standard
method. The detection limits of this ELISA kit for FC
range from 5.3 to 2100 μg/g.
Colonoscopic findings and clinical disease activity
Patients with UC received a magnesium citrate- or poly-
ethylene glycol-based electrolyte solution for bowel prepar-
ation prior to the ileocolonoscopy. All of the procedures
(EVIS 260 series, Olympus, Tokyo, Japan) were performed
by 2 of the authors (K.K. and T.Y.). Patients who under-
went an incomplete colonoscopy examination (cecum not
reached) were excluded, as some with UC had maximum
inflammation in the right colon [30]. Colonoscopic find-
ings were finally determined according to the MES for each
of the 5 portions of the colorectum (cecum to ascending
colon, transverse, descending, sigmoid colon, rectum).
Those determinations were made by the first 5 authors of
this study (K.K., S.I., T.Y., N.F., N.O.), each an experienced
gastroenterologist, within 1 week after the colonoscopy.
When endoscopic grading differed among them, the final
grade was decided based on consensus. We precisely de-
fined the maximum score of MES as M-MES, while the
sum of MES for the 5 colonic segments, which ranged
from 0 to 15 was determined as S-MES. Clinical disease
activity was evaluated on the day of the ileocolonoscopy
using Rachmilewitz’ clinical activity index (CAI) consisting
of 7 subscores, as previously reported [27]. Clinical remis-
sion was defined as a CAI value of 4 or less.
Statistical analysis
Statistical analysis was performed using the SPSS statistical
package (version 19.0, SPSS, Chicago, USA). Parametric
Kawashima et al. BMC Gastroenterology  (2016) 16:47 Page 2 of 6
numerical results are presented as the mean ± standard
deviation (SD), while nonparametric data are presented
as the median and interquartile range (IQR). A Mann-
Whitney test was used to investigate differences be-
tween nonparametric data. Correlation analyses were
performed using Spearman’s rank correlation test. All




The clinical characteristics of the present UC patients
are shown in Table 1. A total of 136 complete colonos-
copies that were accompanied by fecal sample examina-
tions were performed in 102 UC patients. Of those, 32
(24 %) were performed in patients with clinical activity
(CAI ≥5), while the other 104 (76 %) were performed in
those with clinical remission (CAI ≤4). Of the 136
colonoscopies, 68 (50.0 %) were performed for panco-
litis, 36 (26.4 %) for left-sided colitis, and 32 (23.6 %)
for proctitis.
Correlation of FC level with both M-MES and S-MES
As shown in Fig. 1, the median FC level in patients with
an M-MES of 0 (n = 35), 1 (n = 33), 2 (n = 47), and 3
(n = 21) was 35.2 (IQR 17.3-76.6), 103.3 (55.2-336.4),
295.0 (162.9-1000.0), and 751.9 (632.8-1685.6) μg/g, re-
spectively. FC was significantly elevated in accordance
with endoscopic severity and showed a significant
correlation with M-MES (Spearman’s rank correlation
coefficient r = 0.79; p < 0.001). Furthermore, FC dem-
onstrated a strong correlation with S-MES (r = 0.86,
p < 0.001), as shown in Fig. 2. In patients with an M-MES
of 1, 2, and 3, FC demonstrated a significant correlation
with S-MES (r= 0.67, p < 0.001; r = 0.70, p < 0.001; r = 0.47,
p = 0.04, respectively), as shown in Fig. 3a–c. These
results indicated that FC level is correlated with the
extent of affected mucosa even in patients with the same
M-MES value as well as endoscopic severity.
FC levels in patients with the same S-MES, but different
extent of affected mucosa
We also compared FC levels in patients with the
same S-MES, but different extent of affected mucosa.
Of 22 with an S-MES of 2, an MES of 1 in 2 segments
(S-MES = 1 + 1 = 2 points) was seen in 6 and an MES of 2
in only 1 segment (S-MES = 2 points) was seen in 16,
with FC level in the former at 272.2 ± 144.0 μg/g and
at 256.7 ± 192.2 μg/g in the latter, not a significant
difference (p = 0.86).
Discussion
An important element of the present study is that MES
was determined in each of the 5 colonic segments to
evaluate the extent of affected mucosa as well as endo-
scopic severity. Our results clearly showed that FC level
is significantly correlated with both endoscopic severity
and the extent of affected mucosa in patients with UC,
revealing the importance of its measurement as an indi-
cator of mucosal inflammation.





Male 65 (64 %)
Female 47 (36 %)
Number of colonoscopy
Once 71 (70 %)
Twice 28 (27 %)
3 times 3 (3 %)
Complete colonoscopy
Total number 136
Median age in years (IQR) 44.5 (31.0-63.5)
Median duration of disease in years (IQR) 7.0 (4.0-12.5)
Clinical activity
Remission 104 (76 %)
Active 32 (24 %)
Purpose of colonoscopy
Evaluation of disease 46 (34 %)
Surveillance 90 (66 %)
Concomitant medications
Aminosalicylate 129 (95 %)
Topical aminosalicylate 35 (26 %)
Corticosteroids 23 (17 %)
Topical steroids 8 (6 %)
Azathioprine/Mercaptopurine 37 (27 %)
Tacrolimus 11 (8 %)
Biologics 13 (10 %)
Colonoscopic findings (maximum score in colorectum)
Mayo endoscopic subscore 0 35 (26 %)
Mayo endoscopic subscore 1 33 (24 %)
Mayo endoscopic subscore 2 47 (35 %)
Mayo endoscopic subscore 3 21 (15 %)
Biochemical Results
Median C-reactive protein (mg/l) (IQR) 0.05 (0.03-0.12)
Median serum albumin (g/l) (IQR) 4.4 (4.0-4.6)
Median white blood cell count (103×/μL) (IQR) 5.88 (4.86-7.52)
Median hemoglobin (g/dL) (IQR) 13.8 (12.2-14.9)
Median platelet count (104×/μL) (IQR) 24.7 (20.8-29.3)
IQR interquartile range
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FC level has been widely examined in regard to its
correlation with endoscopic activity in UC patients,
with correlation coefficients between FC level and UC
endoscopic activity reported to range from 0.51 to 0.83
[15–21]. In those studies, the endoscopic index for UC
was determined by examining the part of the colorectum
with the most severe inflammation. Similarly, in the
present study, we evaluated mucosal severity in UC
patients using M-MES, and found that the correlation
coefficient between FC level and M-MES was 0.79,
which correlated well with those previous reports.
Thus, our findings confirmed that FC level is correlated
Fig. 1 Scatterplot showing correlation of fecal calprotectin (FC) level
with maximum of Mayo endoscopic subscore (M-MES). The median
and interquartile range (IQR) for FC levels in patients with an M-MES
of 0 (n = 35), 1 (n = 33), 2 (n = 47), and 3 (n = 21) were 35.2 (17.3-76.6),
103.3 (55.2-336.4), 295.0 (162.9-1000.0), and 751.9 (632.8-1685.6) μg/g,
respectively. *p < 0.001, **p < 0.01
Fig. 2 Scatterplot showing correlation of fecal calprotectin (FC) level
with sum of Mayo endoscopic subscore (S-MES) for 5 colonic segments
Fig. 3 Scatterplot showing correlation of fecal calprotectin (FC)
level with sum of Mayo endoscopic subscore for 5 colonic segments
(S-MES) in patients with a maximum MES (M-MES) of 1, 2, and 3.
a M-MES 1. b M-MES 2. c M-MES 3
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with endoscopic severity in the most severely affected
segment of the colorectum.
In most previous reports, the UC endoscopic index
was determined using the most severely affected seg-
ment in the colorectum [23–27]. However, segmental
colonic assessment is becoming increasingly important
in cases of UC according to the United States Food and
Drug Administration [30, 31]. Furthermore, the recent
proposed definition of mucosal healing by the Inter-
national Organization for the study of Inflammatory
Bowel Disease includes absence of friability, blood, ero-
sions, and ulcers in all gastrointestinal mucosa segments
[31]. Another report also noted that the recently devel-
oped UC colonoscopic index of severity (UCCIS) is rele-
vant as an endoscopic index, because of its scoring
system, which evaluates all colonic segments [32]. Thus,
endoscopic assessment of all segments of the colorectum
is recommended for investigating disease extent as well
as severity in UC patients.
To investigate the correlation between FC level and
extent of affected mucosa, we used the sum of MES
(S-MES) in all 5 colonic segments in the preset study, as
MES is the most widely used endoscopic index for UC
and considered to be highly reliable. Very recently, Loba-
ton T, et al. proposed a modified Mayo endoscopic score
as a new endoscopic index for UC, which is calculated
based on analysis of the MES for each of the 5 colonic seg-
ments [33]. In our study, the correlation coefficient value
for the correlation of FC with S-MES was 0.86, nearly as
high as the value (0.73) reported in their study. Further-
more, we found that FC level had a stronger correlation
with S-MES (r = 0.86) as compared to M-MES (r = 0.79),
also similar to that previous study. Based on these results,
we concluded that FC level likely has a stronger correl-
ation with the sum of MES for the 5 colonic segments as
compared to the maximum score of MES.
A novel finding presented in our study that differenti-
ates it from other previous reports is clarification of the
significant correlation of FC level with S-MES, even in
UC patients with the same M-MES value (Fig. 3). Our
results also indicate that FC is elevated in conjunction
with a greater area of affected mucosa even in UC pa-
tients with the same classification of endoscopic severity.
Therefore, we concluded that FC level in UC patients is
important for precise assessment of mucosal inflamma-
tion by showing the extent of affected mucosa as well as
severity. In addition, the correlation coefficient of FC
with S-MES in patients with an M-MES of 3 was com-
paratively low at 0.47 as compared to those in patients
with an M-MES of 1 or 2, though those cannot be dir-
ectly compared. FC level in patients with an M-MES of
3 is higher due to excessive mucosal severity, while the
influence of the extent of affected mucosa on FC level
might be relatively low in those patients.
In addition, we compared FC levels in patients with
the same S-MES, but different extent of affected mu-
cosa. The result suggests that FC level is similar between
patients with mild activity in a greater extent of mucosa
and those with moderate activity in a limited extent.
However, to clearly show this point, examinations of a
larger number of enrolled subjects will be necessary.
Our study has some limitations. First, it was con-
ducted at 2 different hospitals in Japan. To reduce inter-
observer variations as much as possible, before perform-
ing the FC measurement, all colonoscopic findings were
finally determined by 5 experienced gastroenterologists,
each of whom had at least 10 years of experience with per-
forming colonoscopic examinations. However, additional
investigations that include a greater number of institutions
will be necessary. Second, our cohort included few UC pa-
tients with an M-MES of 3, as some of those had difficulty
with providing an adequate fecal sample due to lack of
consistency. In addition, an incomplete colonoscopy may
easily occur in UC patients with an M-MES of 3 due to
their severe condition and pain related to the procedure.
Finally, we did not perform histological examinations of
colonic biopsy samples. Further investigations based on
histological examination findings obtained from all 5 co-
lonic segments including endoscopically non-inflamed
mucosa are necessary for understanding the correlations
of those results with endoscopic findings and FC level.
Conclusions
The present results revealed that FC level is significantly
correlated with the extent of affected mucosa as well as
disease severity in patients with UC, and its measure-
ment is important for precise assessment of mucosal
inflammation.
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